Burroughs Wellcome & Co.: Knowledge, Trust, Profit and the Transformation of the British Pharmaceutical Industry, 1880–1940

by Roy Church and E. M. Tansey
Contents

List of illustrations xi
List of tables xvii
Acknowledgements xix
Archives, locations and abbreviations xx

Foreword by Sir William Castell xxiii
Preface xxv

PART ONE: 1878–1914

1. From trading to manufacturing: S.M. Burroughs & Co. and Burroughs Wellcome & Co., 1878–1888 3
   American origins; Silas Burroughs and John Wyeth & Brother 3
   The trading agency of S.M. Burroughs & Co., 1878–1880 7
   The Kepler Malt Extract Co. 9
   Henry Wellcome and the formation of Burroughs Wellcome & Co. 12
   The medical and economic environment 15
   The partnership’s early financial difficulties 20
   The acquisition of the Kepler Malt Extract Co. 24
   Investment, growth, and development 27
   Production and laboratory experimentation with Kepler Malt Extract; researching for quality 31
   The Stamp Act and the threat to the trade in American proprietary medicines 34
   Competition, costs, and the transition to manufacturing compressed medicines 37

2. Americanisation of the British drug trade: product innovation and ‘creating a demand’ 41
   Products and agency agreements 41
<table>
<thead>
<tr>
<th>Section</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>Products, brands, and markets</td>
<td>42</td>
</tr>
<tr>
<td>Scientific basis for diversification</td>
<td>47</td>
</tr>
<tr>
<td>Broadening the product range; the innovation record</td>
<td>48</td>
</tr>
<tr>
<td>Pricing policies</td>
<td>51</td>
</tr>
<tr>
<td>Advertising ethical medicine; policy, contracts, and content</td>
<td>55</td>
</tr>
<tr>
<td>'Detailing' doctors to create a demand; sales representatives on the road</td>
<td>62</td>
</tr>
<tr>
<td>Researching the market for medicine</td>
<td>66</td>
</tr>
<tr>
<td>Campaigning for contracts; tapping institutional sources of demand</td>
<td>70</td>
</tr>
<tr>
<td>3. 'Quality for profit' through 'science and industry';</td>
<td>73</td>
</tr>
<tr>
<td>management and organisation, labour policies and finance</td>
<td></td>
</tr>
<tr>
<td>Managers, management and organisation</td>
<td>73</td>
</tr>
<tr>
<td>In pursuit of quality: towards control and research</td>
<td>78</td>
</tr>
<tr>
<td>Efficiency and cost control</td>
<td>82</td>
</tr>
<tr>
<td>Flirting with 'scientific management'</td>
<td>87</td>
</tr>
<tr>
<td>Disciplining the workers</td>
<td>90</td>
</tr>
<tr>
<td>Labour recruitment and welfarism</td>
<td>97</td>
</tr>
<tr>
<td>Finance, investment and profit</td>
<td>101</td>
</tr>
<tr>
<td>4. 'Friend and brother' in dysfunctional partnership:</td>
<td>107</td>
</tr>
<tr>
<td>Burroughs versus Wellcome</td>
<td></td>
</tr>
<tr>
<td>The partnership in the 1880s; early disagreements</td>
<td>107</td>
</tr>
<tr>
<td>Issues of ownership, control and management; the renewed partnership agreement of 1885</td>
<td>113</td>
</tr>
<tr>
<td>The case of Burroughs versus Wellcome, 1887–1889</td>
<td>118</td>
</tr>
<tr>
<td>Towards dissolution of the partnership</td>
<td>120</td>
</tr>
<tr>
<td>The death of Burroughs; consequences and his role and impact on the pharmaceutical industry in Britain</td>
<td>124</td>
</tr>
<tr>
<td>5. 'The new crusade'; Burroughs Wellcome &amp; Co. versus the retail trade</td>
<td>130</td>
</tr>
<tr>
<td>Introducing retail price maintenance</td>
<td>130</td>
</tr>
<tr>
<td>Defending brands from substitution</td>
<td>131</td>
</tr>
<tr>
<td>The Tabloid case: Burroughs Wellcome &amp; Co. versus Thomas &amp; Capper</td>
<td>134</td>
</tr>
<tr>
<td>The challenge to retail price maintenance</td>
<td>136</td>
</tr>
<tr>
<td>Substitution and 'trade pirates'; Wellcome versus the retail traders' association</td>
<td>139</td>
</tr>
<tr>
<td>Selling medicine; the role and management of travelling representatives</td>
<td>145</td>
</tr>
</tbody>
</table>
6. Creating products, producing knowledge and gaining respect: research laboratories, 1894–1914

The Wellcome Research Laboratories, 1894–1899

The Home Office and animal experimentation, 1896

The Wellcome Physiological Research Laboratories, 1899–1914

Home Office application, 1900–01

‘I want him to develop my ideals’: Henry Dale’s influence on the WPRL, 1904–1914

Contracts and conditions

Publishing and publications

From animal substances to hormone preparations

The use of the word ‘adrenaline’

Ergot research at the WPRL

Dale as Director of the WPRL, 1906–1914

The Wellcome Chemical Research Laboratories, 1896–1914

Chemical research in the factory and the WCRL, 1897–1914

Wellcome Tropical Research Laboratories, 1902–1913

Wellcome Bureau of Scientific Research

7. Products and prestige: sera and vaccines before the First World War

Serum production — the beginnings and early problems, 1894–96

The Lancet’s report on serum anti-toxins, 1896

Diphtheria diagnosis service

Serum production before the First World War

Development of new anti-sera

Vaccines

Veterinary research and products

8. In search of overseas markets; agencies, depots, branches, and multinational enterprise

Problems and policies

Trading in Europe

Expansion beyond Europe

The Australasian market; the first overseas branch

Initiatives in North America
Origins and development of the New York branch 240
The American branch on the eve of the First World War 246

PART II: 1914–1940

9. The impact of war; innovation and transformation from laboratory research to factory production 255
   The suspension of German trade marks and the drive for synthetic substitute drugs 255
   The haemorrhage of knowledge and skills; the challenge from Jesse Boot 258
   Wellcome, BW&Co., and the wider war effort 263
   From laboratory research to factory production; manufacturing and management 267
   Sera and vaccines 269
   Tetanus 270
   Gas gangrene and other sera and vaccines 272
   Further losses in a competitive market for human resources 273
   Measuring the impact of war 275
   The formation of The Wellcome Foundation Ltd 281

10. Policy formation, research and development 287
    Postwar problems in the research laboratories 287
    Formation of the Scientific and Technical Committee 293
       Professional research staff and the commercial organisation 295
       Research strategy and innovation under the STC 297
       Insulin 299
       Early production problems 299
       Science versus commerce: advertising claims for insulin 306
       Industrial collaboration: British insulin manufacturers 308
    Other drugs and developments 309
       The (eventual) resolution of the ergot problem 309
       Chaulmoogra and derivatives 312
       Other chemotherapy plans 314
    Communication between the laboratories 315
    Research choices, product development and commercial interests: tropical medicine 317
    Patents, publications and research 319

11. Academic reputation counters commercial stigma: sera and vaccines, 1918–1940 325
    Sera and vaccines 325
       Diphtheria anti-toxins: the beginning of the inter-war period 325

BURROUGHS WELLCOME & CO.
Diphtheria susceptibility testing 331
Scarlet fever (scarlatina) 334
TB testing and treatment 339
Influenza, common cold and pneumonia 340
Other products 341
Tropical diseases: yellow fever vaccine 342
Veterinary products 343
Lamb dysentery and related diseases 344
Veterinary research and commerce 346
Foot and mouth disease and tuberculosis: the commercial taint continued 347
Canine distemper vaccine 349
Diphtheria Immunisation: Problems and the end of an era 352
The Ring Case 353
Sulphonamides 356

12. Competition and product development between the wars: Tabloids, Kepler and other 'general goods' 359
The postwar Tabloid range 359
From digitalis to Digoxin 366
Kepler cod liver oil and malt extract and the infant health food market 369
The challenge of vitamins to Kepler goods 371
Vitamin research and marketing policies 376
Vitamin concentrates, natural foods, and Kepler goods 381
The decline of Kepler goods and the search for new products 383

13. Wellcome's American agenda: tariffs, war and the transition to manufacturing at the New York branch 387
Protection, war and policy 387
The formation of the Wellcome Foundation, Burroughs Wellcome (USA) Inc. and the drive for manufacturing at Tuckahoe 389
Marketing and product development 396
Competition and development in the American market 402
Prosperity and depression: Tuckahoe manufacturing and the Tuckahoe Research Laboratory 406
Competition and marketing during the Great Depression 408
Vitamin wars in the USA 412
Product planning and policy; reputation-building and marketing 414
14. A failing business? The nature and origins of decline
   Interpretations and explanations
   BW&Co. in the British pharmaceutical industry
   Financial dimensions; profits, investment, and Wellcome’s
diverse expenditures
   Marketing policies
   Advertising policy; ethical medicines and over-the-counter
   proprietary products
   Product innovation in a competitive environment
   Wellcome’s legacy: the Wellcome Trust
   The Trust’s review of BW&Co.

15. Themes and perspectives: BW&Co., the pharmaceutical
   industry, and medical research
   Scientific ethic, reputation, and profitable business
   Entrepreneurship, management, and under-investment;
   personalities and policies
   Owner-entrepreneur and managers; more dysfunctional
   relationships
   Organisational culture, trust and corporate sclerosis

16. Wellcome’s influence on pharmaceutical and medical
    research in Britain
    The law and animal experimentation
    Standardisation: innovation and diffusion
    People and networks
      Companies and industry
      Academe
      The Royal Society and other professional organisations
      The Medical Research Council and the National Institute for
      Medical Research

Notes and references

Bibliography

Index